PRESS-RELEASE ·Filed Apr 30, 2026

ARGX

argenx SE
BULLISH
Impact 8/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release: earnings
Actionable Insight ▲ Bullish

The massive Q4 beat is already priced in (reported 2/26/2026). Focus on the upcoming Q1 2026 earnings call on May 7 for guidance and pipeline updates. The stock may see modest pre-call positioning but the real catalyst is the Q1 print.

DirectionBullish
Confidencemedium
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
ARGX ▲ +13.70% at T+60d
LONG call ✓ call won +13.70% · α vs SPY +10.59% · entry $781.72 → $888.82
Entry anchored
Apr 30, 2026
via day open
T+1d
+0.23%
call +0.23% · α +0.01%
$783.50
settled 5mo ago
T+5d
+0.72%
call +0.72% · α -1.01%
$787.31
settled 5mo ago
T+20d
+6.94%
call +6.94% · α +1.72%
$835.99
settled 4mo ago
T+60d
+13.70%
call +13.70% · α +10.59%
$888.82
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

argenx reported Q4 2025 EPS of $8.02, a 91.2% beat vs the $4.19 consensus, with revenue of $1.12B in line with estimates. The massive EPS surprise extends a streak of strong quarterly beats, but the press release is a forward-looking notice of an upcoming Q1 2026 earnings call, not the Q4 2025 results themselves, creating ambiguity.

Key Financial Metrics

EPS
$8.02
est $4.19 · +91.4%
Revenue
$1.1B
est $1.1B · 0.0%
Rating
strong beat

Key Facts

  • Q4 2025 EPS of $8.02 vs consensus $4.19, a 91.2% beat
  • Revenue of $1.12B in line with consensus estimates
  • This is a notice for a Q1 2026 earnings call on May 7, 2026, not the Q4 2025 earnings release itself
  • Historical EPS beats: Q3 2025 +18.5%, Q2 2025 +31.7%, Q1 2025 +11.2%

Financial Impact

EPS beat of $3.83 per share vs consensus, representing a 91.2% surprise

eps

Risk Factors

  • The press release is a call notice, not the Q4 earnings release itself, creating a time lag risk
  • Q1 2026 consensus EPS of $5.16 is lower than Q4's $8.02, setting a high bar for sequential performance

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (25 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3284412
14 reports for ARGX
Performance horizon
100% Hit rate 7 of 7 directional calls best @ T+60▲ +30.22%Jun 3, 2026
Filters
Rows
Reports for ARGX — sortable, filterable
TypeNow
Sep 10, 2026
22d ago
Institutional Cluster
MIXED ★ 5/10
$984.04 $995.77▲ +1.19%▲ +1.69%$918.23 (−6.69%)
Aug 17, 2026
6w ago
6-K
BULLISH ★ 8/10
$987.84 $1,011.11▲ +2.36%▲ +3.55%$918.23 (−7.05%)
Aug 6, 2026
8w ago
Press Release
BULLISH ★ 7/10
$875.30 $856.94▼ −2.10%▼ −3.31%$918.23 (+4.91%)
Jul 27, 2026
9w ago
6-K
BULLISH ★ 7/10
$888.82 $853.82▼ −3.94%▼ −5.01%$918.23 (+3.31%)
Jul 27, 2026
9w ago
Press Release
BULLISH ★ 7/10
$888.82 $853.82▼ −3.94%▼ −5.01%$918.23 (+3.31%)
Jul 23, 2026
10w ago
Press Release
NEUTRAL ★ 5/10
$924.60 $872.58▼ −5.63%▼ −6.10%$918.23 (−0.69%)
Jul 16, 2026
11w ago
Press Release
NEUTRAL ★ 2/10
$857.97 $924.60▲ +7.77%▲ +9.44%$918.23 (+7.02%)
Jun 23, 2026
14w ago
6-K
NEUTRAL ★ 4/10
$853.40 $912.46▲ +6.92%▲ +5.91%$918.23 (+7.60%)
Jun 3, 2026
17w ago
6-K
BULLISH ★ 5/10
$813.14 $862.18▲ +6.03%▲ +9.85%$918.23 (+12.92%)
May 8, 2026
20w ago
Press Release
BULLISH ★ 7/10
$813.28 $776.26▼ −4.55%▼ −4.47%$918.23 (+12.91%)
Showing 10 of 14

US Market Status

Market Open — Closes in 2h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 30, 2026